Panacea Biotec Limited (NSEI: PANACEABIO)
Health Care · Biotechnology · IN
Rs411.10
+3.70% today · +1.9% 1Y
Panacea Biotec Limited (NSEI: PANACEABIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $263.17M and employs 2,149 people.
Over the last twelve months the share price has gained 1.9%, trading between 292.40 and 647.00.
Tweenvest scores Panacea Biotec Limited across four factors: quality 64/100, value 56/100, growth 56/100. Its strongest factor is quality.
PANACEABIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $263.17M
- Revenue (TTM)
- $71.14M
- P/E
- —
- EPS
- -1.17
- Dividend yield
- —
- Beta (5Y)
- 0.28
- 52-week high
- Rs647.00
- 52-week low
- Rs292.40
- Avg volume (3M)
- —
- Shares outstanding
- 61.25M
- Employees
- 2,149
- Next earnings
- —
About Panacea Biotec Limited
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, with operations segmented into Vaccines and Formulations. The company's pharmaceutical offerings comprise proprietary medicines targeting diverse medical fields such as pain management, diabetes, cardiovascular health, oncology, renal disease, osteoporosis, anti-tubercular therapy, and gastro-intestinal care. In addition to these, Panacea Biotec develops and distributes vaccines for conditions like anthrax, dengue, and Japanese encephalitis, among others. The firm maintains a robust global presence, exporting its goods to over 30 countries, including key markets such as the United States, Germany, the Russian Federation, Sri Lanka, and the Philippines. Notably, Panacea Biotec has established significant strategic alliances, including a partnership with the Russian Direct Investment Fund for the manufacture of the Sputnik-V COVID-19 vaccine. It also collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Translational Health Science and Technology Institute (THSTI) to pioneer vaccine candidates designed to combat SARS-CoV-2 variants and other beta coronaviruses.
- ISIN
- INE922B01023
- Founded
- 1984
- Listed since
- Jul 1, 2002
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.72 | +0.35% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $445.50 | +0.74% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.50 | -0.21% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.